Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
Clinical trial NCT03379259 · TERMINATED
Trial details
- NCT number
- NCT03379259
- Sponsor
- BeiGene
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-27
- Primary completion
- 2020-09-08
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.